Gil Leurquin-Sterk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gil Leurquin-Sterk has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Nicola Trotta
Medical Physics Department, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium
3 shared publications - Serge Goldman
Université Libre de Bruxelles (ULB)
2 shared publications - Antoine Noel
CUB Hôpital Erasme
1 shared publication - Christine Decaestecker
Laboratory of Image Synthesis and Analysis, Université Libre de Bruxelles, Brussels, Belgium; DIAPath, CMMI, Université Libre de Bruxelles, Gosselies, Belgium
1 shared publication - Corentin Martens
Department of Nuclear Medicine, Hôpital Erasme, Université Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium
1 shared publication - Florence Lefranc
Service de Neurochirurgie, Hôpital Erasme, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium
1 shared publication
Latest Publications
- Open Access
- 20 February 2025
- Published by Science Publishing Group in International Journal of Neurosurgery
- Vol. 9 (1) , 30-40
Gamma-Knife Thalamotomy for Essential and Parkinsonian Tremor: Predicting Response to Treatment Using Pre-Therapeutic Cerebral FDG-PET
Essential tremor and parkinsonian tremor affect approximately 5–7% of individuals over the age of 65. Pharmacological therapies yield sustained clinical improvement in only about 50% of cases. For patients ineligible for deep brain stimulation, Gamma Knife thalamotomy (GKVIM) offers a non-invasive alternative, demonstrating a tremor reduction efficacy of 70–80%, typically with a latency of approximately 4.8 months. This study aimed to identify regional cerebral metabolic patterns predictive of clinical response to GKVIM using [¹ 8 F]-FDG positron emission tomography (FDG-PET). Fifteen consecutive patients diagnosed with essential tremor (n=10) or parkinsonian tremor (n=5) underwent preoperative cerebral FDG-PET imaging within 24 hours prior to GKVIM at Erasme University Hospital between January 2020 and January 2023. All patients were clinically followed for a minimum of six months (mean follow-up: 9 ± 3 months) by experienced neurologists or neurosurgeons. Statistical Parametric Mapping (SPM) was used to compare metabolic patterns between treatment responders (n=11; 73%) and non-responders (n=4) to identify potential predictors of therapeutic response. As a secondary objective, metabolic differences between patients with essential tremor and healthy controls (n=54) were analyzed to explore neurobiological correlates of disease pathophysiology. Those analysis revealed that responders exhibited significant hypometabolism in the prefrontal cortex and supramarginal gyrus, alongside cerebellar hypermetabolism. In the secondary analysis, patients with essential tremor demonstrated distinct metabolic alterations, notably involving the inferior olivary nuclei. This study thus identifies specific regional cerebral metabolic patterns associated with favourable clinical response to Gamma Knife thalamotomy, suggesting potential neuroimaging biomarkers for patient selection. Moreover, the observed metabolic changes provide additional insight into the pathophysiological mechanisms underlying essential tremor.
- 20 February 2025
- Published by Science Publishing Group in International Journal of Neurosurgery
- Vol. 9 (1) , 30-40
Open AccessGamma-Knife Thalamotomy for Essential and Parkinsonian Tremor: Predicting Response to Treatment Using Pre-Therapeutic Cerebral FDG-PET
Essential tremor and parkinsonian tremor affect approximately 5–7% of individuals over the age of 65. Pharmacological therapies yield sustained clinical improvement in only about 50% of cases. For patients ineligible for deep brain stimulation, Gamma Knife thalamotomy (GKVIM) offers a non-invasive alternative, demonstrating a tremor reduction efficacy of 70–80%, typically with a latency of approximately 4.8 months. This study aimed to identify regional cerebral metabolic patterns predictive of clinical response to GKVIM using [¹ 8 F]-FDG positron emission tomography (FDG-PET). Fifteen consecutive patients diagnosed with essential tremor (n=10) or parkinsonian tremor (n=5) underwent preoperative cerebral FDG-PET imaging within 24 hours prior to GKVIM at Erasme University Hospital between January 2020 and January 2023. All patients were clinically followed for a minimum of six months (mean follow-up: 9 ± 3 months) by experienced neurologists or neurosurgeons. Statistical Parametric Mapping (SPM) was used to compare metabolic patterns between treatment responders (n=11; 73%) and non-responders (n=4) to identify potential predictors of therapeutic response. As a secondary objective, metabolic differences between patients with essential tremor and healthy controls (n=54) were analyzed to explore neurobiological correlates of disease pathophysiology. Those analysis revealed that responders exhibited significant hypometabolism in the prefrontal cortex and supramarginal gyrus, alongside cerebellar hypermetabolism. In the secondary analysis, patients with essential tremor demonstrated distinct metabolic alterations, notably involving the inferior olivary nuclei. This study thus identifies specific regional cerebral metabolic patterns associated with favourable clinical response to Gamma Knife thalamotomy, suggesting potential neuroimaging biomarkers for patient selection. Moreover, the observed metabolic changes provide additional insight into the pathophysiological mechanisms underlying essential tremor.
- Open Access
Voxelwise Principal Component Analysis of Dynamic [S-Methyl-11C]Methionine PET Data in Glioma Patients
Recent works have demonstrated the added value of dynamic amino acid positron emission tomography (PET) for glioma grading and genotyping, biopsy targeting, and recurrence diagnosis. However, most of these studies are based on hand-crafted qualitative or semi-quantitative features extracted from the mean time activity curve within predefined volumes. Voxelwise dynamic PET data analysis could instead provide a better insight into intra-tumor heterogeneity of gliomas. In this work, we investigate the ability of principal component analysis (PCA) to extract relevant quantitative features from a large number of motion-corrected [S-methyl-11C]methionine ([11C]MET) PET frames. We first demonstrate the robustness of our methodology to noise by means of numerical simulations. We then build a PCA model from dynamic [11C]MET acquisitions of 20 glioma patients. In a distinct cohort of 13 glioma patients, we compare the parametric maps derived from our PCA model to these provided by the classical one-compartment pharmacokinetic model (1TCM). We show that our PCA model outperforms the 1TCM to distinguish characteristic dynamic uptake behaviors within the tumor while being less computationally expensive and not requiring arterial sampling. Such methodology could be valuable to assess the tumor aggressiveness locally with applications for treatment planning and response evaluation. This work further supports the added value of dynamic over static [11C]MET PET in gliomas.
Open AccessVoxelwise Principal Component Analysis of Dynamic [S-Methyl-11C]Methionine PET Data in Glioma Patients
Recent works have demonstrated the added value of dynamic amino acid positron emission tomography (PET) for glioma grading and genotyping, biopsy targeting, and recurrence diagnosis. However, most of these studies are based on hand-crafted qualitative or semi-quantitative features extracted from the mean time activity curve within predefined volumes. Voxelwise dynamic PET data analysis could instead provide a better insight into intra-tumor heterogeneity of gliomas. In this work, we investigate the ability of principal component analysis (PCA) to extract relevant quantitative features from a large number of motion-corrected [S-methyl-11C]methionine ([11C]MET) PET frames. We first demonstrate the robustness of our methodology to noise by means of numerical simulations. We then build a PCA model from dynamic [11C]MET acquisitions of 20 glioma patients. In a distinct cohort of 13 glioma patients, we compare the parametric maps derived from our PCA model to these provided by the classical one-compartment pharmacokinetic model (1TCM). We show that our PCA model outperforms the 1TCM to distinguish characteristic dynamic uptake behaviors within the tumor while being less computationally expensive and not requiring arterial sampling. Such methodology could be valuable to assess the tumor aggressiveness locally with applications for treatment planning and response evaluation. This work further supports the added value of dynamic over static [11C]MET PET in gliomas.
- Open Access
Structural and metabolic brain abnormalities in COVID-19 patients with sudden loss of smell
Objectives: Sudden loss of smell is a very common symptom of coronavirus disease 19 (COVID-19). This study characterizes the structural and metabolic cerebral correlates of dysosmia in patients with COVID-19. Methods: Structural brain magnetic resonance imaging (MRI) and positron emission tomography with [18F]-fluorodeoxyglucose (FDG-PET) were prospectively acquired simultaneously on a hybrid PET-MR in twelve patients (2 males, 10 females, mean age: 42.6 years, age range: 23-60 years) with sudden dysosmia and positive detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on nasopharyngeal swab specimens. FDG-PET data were analysed using a voxel-based approach and compared with that of a group of healthy subjects. Results: Bilateral blocking of the olfactory cleft was observed in six patients, while subtle olfactory bulb asymmetry was found in three patients. No MRI signal abnormality downstream of the olfactory tract was observed. Heterogeneous (decrease or increase) glucose metabolism abnormalities were observed in core olfactory and high-order neocortical areas. A modulation of regional cerebral glucose metabolism by the severity and the duration of COVID-19-related dysosmia was disclosed using correlation analyses. Conclusions: This PET-MR study shows that sudden loss of smell in COVID-19 is not related to central involvement due to SARS-CoV-2 neuroinvasiveness. Loss of smell is associated with heterogeneous cerebral metabolic changes in core olfactory and high-order cortical areas likely related to combined processes of deafferentation and active functional reorganisation secondary to the lack of olfactory stimulation.
Open AccessStructural and metabolic brain abnormalities in COVID-19 patients with sudden loss of smell
Objectives: Sudden loss of smell is a very common symptom of coronavirus disease 19 (COVID-19). This study characterizes the structural and metabolic cerebral correlates of dysosmia in patients with COVID-19. Methods: Structural brain magnetic resonance imaging (MRI) and positron emission tomography with [18F]-fluorodeoxyglucose (FDG-PET) were prospectively acquired simultaneously on a hybrid PET-MR in twelve patients (2 males, 10 females, mean age: 42.6 years, age range: 23-60 years) with sudden dysosmia and positive detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on nasopharyngeal swab specimens. FDG-PET data were analysed using a voxel-based approach and compared with that of a group of healthy subjects. Results: Bilateral blocking of the olfactory cleft was observed in six patients, while subtle olfactory bulb asymmetry was found in three patients. No MRI signal abnormality downstream of the olfactory tract was observed. Heterogeneous (decrease or increase) glucose metabolism abnormalities were observed in core olfactory and high-order neocortical areas. A modulation of regional cerebral glucose metabolism by the severity and the duration of COVID-19-related dysosmia was disclosed using correlation analyses. Conclusions: This PET-MR study shows that sudden loss of smell in COVID-19 is not related to central involvement due to SARS-CoV-2 neuroinvasiveness. Loss of smell is associated with heterogeneous cerebral metabolic changes in core olfactory and high-order cortical areas likely related to combined processes of deafferentation and active functional reorganisation secondary to the lack of olfactory stimulation.